What pharmacologic option might be considered when a CKD patient on phosphate control still has high PTH?

• A. Bisphosphonates
• B. Calcimimetics Such As Cinacalcet Or Etelcalcetide
• C. Loop Diuretics
• D. ACE Inhibitors

Answer: (B)

The key idea is managing persistent secondary hyperparathyroidism in CKD after phosphate control. When phosphate is managed but PTH remains elevated, a calcimimetic is used because it directly lowers PTH by increasing the parathyroid gland’s sensitivity to calcium. These drugs act on the calcium-sensing receptor on parathyroid cells, so even with lower or normal calcium levels, PTH secretion drops. This helps control bone-mineral disease in CKD. Examples include cinacalcet and etelcalcetide, which are commonly used in dialysis patients or those with high PTH despite phosphate control and vitamin D therapy. Monitor calcium, phosphorus, and PTH after starting, since calcimimetics can cause hypocalcemia.

Bisphosphonates target bone resorption rather than PTH secretion, so they don’t address elevated PTH in CKD. Loop diuretics and ACE inhibitors don't directly reduce PTH either; loop diuretics can affect calcium balance and ACE inhibitors mainly protect kidney function and blood pressure, not parathyroid hormone levels.